Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

A method of treating a patient suffering from an ophthalmic condition, the method comprising:

• determining whether the patient has an angiopoietin like 7 (ANGPTL7) predicted loss-of-function variant nucleic acid molecule encoding a human ANGPTL7 polypeptide by:
• performing or having performed a genotyping assay on a biological sample from the patient to determine if the patient has a genotype comprising the ANGPTL7 predicted loss-of-function variant nucleic acid molecule;
• and
• administering or continuing to administer to a patient that is ANGPTL7 reference a second therapeutic agent that treats or inhibits the ophthalmic condition in a standard dosage amount, and administering to the patient an ANGPTL7 inhibitor, wherein the second therapeutic agent is not an ANGPTL7 inhibitor;
• and
• administering or continuing to administer to a patient that is heterozygous for the ANGPTL7 predicted loss-of-function variant a second therapeutic agent that treats or inhibits the ophthalmic condition in an amount that is the same as or lower than a standard dosage amount, and administering to the patient an ANGPTL7 inhibitor, wherein the second therapeutic agent is not an ANGPTL7 inhibitor;
• wherein the presence of a genotype having the ANGPTL7 predicted loss-of-function variant nucleic acid molecule encoding the human ANGPTL7 polypeptide indicates the patient has a reduced risk of developing the ophthalmic condition;
• wherein the ANGPTL7 predicted loss-of-function variant nucleic acid molecule is a nucleic acid molecule encoding ANGPTL7 Arg177Stop or Trp188Stop.